Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors

Neuroscience

Volumn 241, Issue , 2013, Pages 147-156

  de la Salle, S ^a   Smith, D ^a,b   Choueiry, J ^a,b   Impey, D ^a,b   Philippe, T ^b   Dort, H ^b   Millar, A ^b   Albert, P ^b   Knott, V ^a,b  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Baseline dependency; Catechol O methyltransferase; Nicotine; Non smokers; P50 sensory gating; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; METHIONINE; NICOTINE GUM; PLACEBO; VALINE;

ADULT; AMPLITUDE MODULATION; ARTICLE; CATECHOL METHYLTRANSFERASE GENE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINE GENE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GENE LOCATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROMODULATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY GATING; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STIMULUS RESPONSE; TREATMENT DURATION; WAVEFORM;

ADOLESCENT; ADULT; CATECHOL O-METHYLTRANSFERASE; DOUBLE-BLIND METHOD; EVOKED POTENTIALS; GENOTYPE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; REAL-TIME POLYMERASE CHAIN REACTION; SENSORY GATING; YOUNG ADULT;

EID: 84876706834     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.03.029     Document Type: Article

References (63)

1. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992, 32:607-616.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993, 150:1856-1861.
3. Adler L.E., Olincy A., Cawthra E.M., McRae K.A., Harris J.G., Nagamoto H.T., Waldo M.C., Hall M.H., Bowles A., Woodward L., Ross R.G., Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 2004, 161:1822-1828.
4. Allman A.A., Benkelfat C., Durand F., Sibon I., Dagher A., Leyton M., Baker G.B., O'Driscoll G.A. Effect of d-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacology (Berl) 2010, 211:423-433.
5. Benwell M.E., Balfour D.J., Anderson J.M. Evidence that tobacco smoking increases the density of (-)-[3H] nicotine binding sites in human brain. J Neurochem 1988, 50:1243-1247.
6. Bilder R.M., Volavka J., Lachman H.M., Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004, 29:1943-1961.
7. Boutros N.N., Brockhaus-Dumke A., Gjini K., Vedeniapin A., Elfakhani M., Burroughs S., Keshavan M. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophr Res 2009, 113:339-346.
8. Boutros N.N., Korzyukov O., Jansen B., Feingold A., Bell M. Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res 2004, 126:203-215.
9. Brenner C., Kieffaber P.D., Clementz B.A., Johannesen J.K., Shekhar A., O'Donnell B.F., Hetrick W.P. Event-related potential abnormalities in schizophrenia: a failure to "gate in" salient information?. Schizophr Res 2009, 113:332-338.
10. Cao Y.A., Featherstone R.E., Gandal M.J., Liang Y., Jutzeler C., Saunders J., Tatard-Leitman V., Chen J., Weinberger D.R., Lerman C., Siegel S.J. Nicotine normalizes event related potentials in COMT-Val-tg mice and increases gamma and theta spectral density. Behav Neurosci 2012, 126:332-343.
11. Clementz B.A. Psychophysiological measures of (dis)inhibition as liability indicators for schizophrenia. Psychophysiology 1998, 35:648-668.
12. Clementz B.A., Geyer M.A., Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr Res 1998, 30:71-80.
13. Colzato L.S., Waszak F., Nieuwenhuis S., Posthuma D., Hommel B. The flexible mind is associated with the catechol-O-methyltransferase (COMT) Val158Met polymorphism: evidence for a role of dopamine in the control of task-switching. Neuropsychologia 2010, 48:2764-2768.
14. Crawford H.J., McClain-Furmanski D., Castagnoli N., Castagnoli K. Enhancement of auditory sensory gating and stimulus-bound gamma band (40Hz) oscillations in heavy tobacco smokers. Neurosci Lett 2002, 317:151-155.
15. Croft R.J., Dimoska A., Gonsalvez C.J., Clarke A.R. Suppression of P50 evoked potential component, schizotypal beliefs and smoking. Psychiatry Res 2004, 128:53-62.
16. Csomor P.A., Stadler R.R., Feldon J., Yee B.K., Geyer M.A., Vollenweider F.X. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 2008, 33:497-512.
17. Dalecki A., Croft R., Johnstone S. An evaluation of P50 paved-click methodologies. Psychophysiology 2011, 48:1692-1700.
18. Dani J., De Biasi M. Cellular mechanism of nicotine addiction. Pharmacol Biochem Behav 2001, 70:439-446.
19. de Leon J., Diaz F. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviours. Schizophr Res 2005, 76:135-157.
20. de Wilde O., Bour L., Dingemans P., Koelman J., Linszen D. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res 2007, 97:137-151.
21. Durstewitz D., Seamans J.K. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-O-methyltransferase genotypes and schizophrenia. Biol Psychiatry 2008, 64:739-749.
22. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001, 98:6917-6922.
23. Flatscher-Bader T., Wilce P.A. The effect of alcohol and nicotine abuse on gene expression in the brain. Nutr Res Rev 2009, 22:148-162.
24. Freedman R., Leonard S., Gault J.M., Hopkins J., Cloninger C.R., Kaufmann C.A., Tsuang M.T., Farone S.V., Malaspina D., Svrakic D.M., Sanders A., Gejman P. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 2001, 105:20-22.
25. Freedman R., Waldo M., Bickford-Wimer P., Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schizophr Res 1991, 4:233-243.
26. Fuerst D., Gallinat J., Boutros N. Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology 2007, 44:620-626.
27. Goldberg T.E., Weinberger D.R. Genes and the parsing of cognitive processes. Trends Cogn Sci 2004, 8:325-335.
28. Goldman-Rakic P.S., Muly E.C., Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000, 31:295-301.
29. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41:1-24.
30. Gratton G., Coles M., Conchin E. A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol 1983, 55:468-484.
31. Heishman S.J., Kleykamp B.A., Singleton E.G. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 2010, 210:453-469.
32. Hetrick W., Sandman C., Bunney W., Jin Y., Potkin S., White M. Gender differences in gating of the auditory evoked potential in normal subjects. Biol Psychiatry 1996, 39:51-58.
33. Holstein D., Csmor P., Geyer M., Huber T., Brugger N., Sluderus E., Vollenweider X. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. J Psychopharmacol 2011, 25:1600-1613.
34. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005, 57:79-115.
35. Knott V., Fisher D., Millar A. Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors. Neuroscience 2010, 170:816-826.
36. Knott V., Millar A., Fisher D. Sensory gating and source analysis of the auditory P50 in low and high suppressors. Neuroimage 2009, 44:992-1000.
37. Knott V., Millar A., Fisher D., Albert P. Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism. Neuroscience 2010, 166:145-156.
38. Kumari V., Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005, 29:1021-1034.
39. Light G., Braff D. Sensory gating deficits in schizophrenia: can we parse the effects of medication, nicotine use, and changes in clinical status?. Clin Neurosci Res 2003, 3:47-54.
40. Loughead J., Wileyto E.P., Valdez J.N., Sanborn P., Tang K., Strasser A.A., Ruparel K., Ray R., Gur R.C., Lerman C. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol Psychiatry 2009, 14:820-826.
41. Lu B.Y., Martin K.E., Edgar J.C., Smith A.K., Lewis S.F., Escamilla M.A., Miller G.A., Cañive J.M. Effect of catechol O-methyltransferase val(158)met polymorphism on the p50 gating endophenotype in schizophrenia. Biol Psychiatry 2007, 62:822-825.
42. Majic T., Rentzsch J., Gudlowski Y., Ehrlich S., Juckel G., Sander T., Lang U.E., Winterer G., Gallinat J. COMT Val108/158Met genotype modulates human sensory gating. Neuroimage 2011, 55:818-824.
43. Maxwell M (1992) Family Interview for Genetic Studies (FIGs): manual for FIGs. Clinical Neurogenetics Branch, Intramural Research Program. National Institutes of Mental Health, Bethesda, MD.
44. Millar A., Smith D., Choueiry J., Fisher D., Albert P., Knott V. The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. Neuroscience 2011, 180:148-156.
45. Monte-Silva K., Kuo M.F., Thirugnanasambandam N., Liebetanz D., Paulus W., Nitsche M.A. Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans. J Neurosci 2009, 29:6124-6131.
46. Newhouse P.A., Potter A., Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 2004, 4:36-46.
47. Nolan K.A., Bilder R.M., Lachman H.M., Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 2004, 161:359-361.
48. Olincy A., Braff D.L., Adler L.E., Cadenhead K.S., Calkins M.E., Dobie D.J., Green M.F., Greenwood T.A., Gur R.E., Gur R.C., Light G.A., Mintz J., Nuechterlein K.H., Radant A.D., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Wagner B.D., Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res 2010, 119:175-182.
49. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., Potkin S., Bunney W.E. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008, 158:226-247.
50. Perkins K.A. Baseline-dependency of nicotine effects: a review. Behav Pharmacol 1999, 10:597-615.
51. Petrovsky N., Ettinger U., Quednow B.B., Walter H., Schnell K., Kessler H., Mössner R., Maier W., Wagner M. Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacology (Berl) 2012, 221:27-38.
52. Picciotto M.R., Addy N.A., Mineur Y.S., Brunzell D.H. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 2008, 84:329-342.
53. Potter D., Summerfelt A., Gold J., Buchanan R. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 2006, 32:692-700.
54. Rosa E.C., Dickinson D., Apud J., Weinberger D.R., Elvevåg B. COMT Val158Met polymorphism, cognitive stability and cognitive flexibility: an experimental examination. Behav Brain Funct 2010, 6:53.
55. Shaikh M., Hall M.H., Schulze K., Dutt A., Walshe M., Williams I., Constante M., Picchioni M., Toulopoulou T., Collier D., Rijsdijk F., Powell J., Arranz M., Murray R.M., Bramon E. Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis?. Psychol Med 2011, 41:263-276.
56. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006, 60:141-151.
57. Turetsky B.I., Greenwood T.A., Olincy A., Radant A.D., Braff D.L., Cadenhead K.S., Dobie D.J., Freedman R., Green M.F., Gur R.E., Gur R.C., Light G.A., Mintz J., Nuechterlein K.H., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Calkins M.E. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry 2008, 64:1051-1059.
58. Vollenweider F.X., Barro M., Csomor P.A., Feldon J. Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol Psychiatry 2006, 60:597-603.
59. Wan L., Friedman B.H., Boutros N.N., Crawford H.J. P50 sensory gating and attentional performance. Int J Psychophysiol 2008, 67:91-100.
60. Williams J., Gibbon M., First M., Spitzer R., Davies M., Borus J., Howes M., Kane J., Pope H., Rovasaville B. The Structured Clinical Interview for the DSM-III-R (SCID II). Multisite test-retest reliability. Arch Gen Psychiatry 1992, 49:630-636.
61. Williams H.J., Owen M.J., O'Donovan M.C. Is COMT a susceptibility gene for schizophrenia?. Schizophr Bull 2007, 33:635-641.
62. Williams-Gray C.H., Hampshire A., Robbins T.W., Owen A.M., Barker R.A. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007, 27:4832-4838.
63. Winterer G. Why do patients with schizophrenia smoke?. Curr Opin Psychiatry 2010, 23:112-119.